PCM
NTLA icon

Pinz Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Pinz Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-900
Closed -$146K – 310
2021
Q2 		$146K Buy
+900
New +$70.1K 0.04% 118
2021
Q1 		– Sell
-44,000
Closed -$2.39M – 350
2020
Q4 		$2.39M Buy
+44,000
New +$1.6M 1.09% 39
2020
Q3 		– Sell
-61,950
Closed -$1.3M – 160
2020
Q2 		$1.3M Buy
+61,950
New +$1.05M 0.6% 83

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pinz Capital Management's NTLA Position: Q3 2021 in Review

Pinz Capital Management sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 900 shares — an estimated $146K sold.

Pinz Capital Management first reported a position in NTLA in Q2 2020 and held it in 3 quarters. The position peaked at $2.39M in Q4 2020. 364 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

  • Pinz Capital Management reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 900 Intellia Therapeutics shares in Q3 2021, an estimated $146K.
  • Pinz Capital Management first reported a position in Intellia Therapeutics in Q2 2020 and held it in 3 quarters.
  • Pinz Capital Management's Intellia Therapeutics position peaked at $2.39M in Q4 2020.
  • 364 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.